PILA PHARMA AB Logo

PILA PHARMA AB

Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.

PILA | ST

Overview

Corporate Details

ISIN(s):
SE0015988274
LEI:
6488Z7WG18Q0ZN0V0262
Country:
Sweden
Address:
Norra Vallgatan 72, 211 22 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PILA PHARMA AB is a clinical-stage biopharmaceutical company focused on developing a potential first-in-class oral treatment for metabolic diseases, primarily type 2 diabetes and obesity. The company's lead candidate, XEN-D0501, is a TRPV1 antagonist, representing a novel therapeutic approach with a different mechanism of action compared to mainstream treatments. The company's strategy emphasizes the development of a convenient oral tablet to address the large global patient population. PILA PHARMA is actively advancing its clinical program, with a recent strategic focus on dedicated obesity studies aimed at generating a comprehensive data package to facilitate future partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PILA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PILA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS
SKINBIOTHERAPEUTICS PLC Logo
A life science company developing microbiome-based skin health products and supplements.
United Kingdom SBTX
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.